HuiXian Medical Completes Tens of Millions RMB Financing Round to Build a Global Leading Smart Diagnostics Platform

HEMOSMART MEDICAL TECHNOLOGY LTD completed a financing round worth tens of millions of yuan in early October 2021. The round was led by the CDIB Capital Group’s HuaChuang Biomedical Fund, with participation from existing shareholders. The proceeds will be used for the research and development and registration of new products, as well as for building a global marketing system.

Hemosmart Medical, established in late 2018, is an independent innovative medical device company whose core R&D team originates from the Microfluidics Laboratory at the University of Cambridge, UK.

Targeting the global in vitro diagnostics (IVD) market, valued at trillions, HEMOSMART MEDICAL TECHNOLOGY LTD leverages microfluidic chips and algorithms as its core technologies to precisely control fluidics, timing, accuracy, and costs. Committed to transforming current testing practices, the company provides comprehensive “Smart Testing” solutions, including automated, rapid point-of-care testing (POCT) IVD devices, microfluidic chips, and diagnostic reagent kits, with a focus on rapid detection in the fields of oncology, infectious diseases, and chronic diseases.

HEMOSMART MEDICAL TECHNOLOGY LTD has established R&D centers and ISO 13485-certified production facilities in Pudong, Shanghai, and Kunshan, Suzhou. Since its inception over two years ago, the company has developed more than 190 proprietary intellectual property rights and launched over 30 products. By maintaining close collaborations with leading domestic and international research institutions and top-tier hospitals, and by participating in major projects such as those funded by the National Natural Science Foundation of China, HEMOSMART serves both domestic and global markets with its comprehensive product portfolio, striving to become a global leader in smart diagnostics.

Liang Xiaozheng, Director of the Huachuang Biomedical Fund at CDIB Capital Group: “We are optimistic about the industry trend toward fully automated, integrated microfluidic in vitro diagnostic (IVD) instruments and reagents. The challenges posed by the COVID-19 pandemic have further underscored the importance and normalization of disease control within this sector. HEMOSMART MEDICAL TECHNOLOGY LTD stands out as a high-quality enterprise in this field based on our evaluation. Its exceptional team has developed instruments and reagent products that address the latest scientific, clinical, and market demands, and its strong execution capabilities have left a deep impression on us. With product approvals and market launches scheduled over the next two years, the company is poised to enter a phase of rapid growth. CDIB is honored to lead this financing round for HEMOSMART MEDICAL TECHNOLOGY LTD, and we look forward to seeing it become a unicorn in the future smart diagnostics landscape, contributing to the development of China’s broader health industry.”

CDIB Capital Group is a leading pan-Asian investment institution with capabilities spanning private equity, venture capital, and debt financing. Its investment focus centers on advanced manufacturing, healthcare, consumer sectors, and technology services, dedicated to identifying and capitalizing on cross-border investment opportunities across the Asia-Pacific region. The firm boasts over sixty years of investment experience and an investment team of more than 100 professionals. CDIB Capital Group’s parent company is China Development Financial Holding Corporation (CDF), which has total assets of approximately USD 125 billion. Headquartered in Taipei, China, CDF has established teams in Hong Kong and Shanghai (China), Singapore, Bangkok, Jakarta, and New York.